External quality assessment for warfarin dosing using computerised decision support software

T P Oppenkowski, E T Murray, H Sandhar, D A Fitzmaurice

J Clin Pathol 2003;56:605–607

Aim: To establish and evaluate an external quality assessment scheme for warfarin dosing for users of a computerised decision support system, BAP-PC.

Design: Analysis of 12 months of clinical data from 10 primary care centres using BAP-PC within an oral anticoagulation clinic. Data were analysed for individual centres and compared with aggregated data for all practices. Individual feedback forms were provided to participating centres.

Results: A total patient population of 367 (range, 17–65/centre) was analysed. On average, patients spent 69% of time in the therapeutic range (range, 60–76%). Patients were seen on average every 27 days (range, 24–30). The average point prevalence was 86% (range, 76–100%). In total, 33 adverse events were reported (0–13/practice). Serious adverse events ranged from 0 to 1 for each practice. This translates into a serious adverse event rate of 1.6/100 patient years.

Conclusions: Practices were successful in maintaining good therapeutic international normalised ratio control, with centres achieving 50% or higher time in range. There are some doubts about the quality of data collection at a practice level because there were no reported events in half of the participating centres. The observed event rates do concur with previously reported data, however. Further cycles of the scheme are necessary to establish it as a useful research and benchmarking tool.

The number of patients receiving oral anticoagulant treatment (primarily warfarin in the UK) has increased exponentially over the past decade, because of the increased use of warfarin as a thromboprophylactic agent in non-rheumatic atrial fibrillation.1–4 One important development that has arisen out of a need to facilitate the management of this increase has been the use of computerised decision support systems (CDSS) to assist with the dosing of warfarin within both primary and secondary care clinics.

Previous studies have shown that the use of a CDSS for determining the dose of warfarin can result in improved quality of therapeutic control when compared with manual dosing systems.5–8 In addition, the process of performing clinical audit is made easier through CDSS and may be more reliable because of it.

The Birmingham Anticoagulation Programme for Primary Care (BAP-PC) is a CDSS that has been used by primary care centres in the UK since 1998. The software incorporates a modification of the validated “Coventry equation” for translation of international normalised ratio (INR) results into warfarin doses.9–11

“...the relatively narrow therapeutic window for successful oral anticoagulation continues to make therapeutic management a difficult task”

Historically, although great efforts have been made to ensure that the therapeutic haemostatic deficit induced by warfarin is measured accurately,9,12 the relatively narrow therapeutic window for successful oral anticoagulation continues to make therapeutic management a difficult task.13 The need for consistency and accuracy of measuring the induced deficit has led to the development of the INR, the international sensitivity index, and external quality assessment (EQA) schemes. EQA is an essential element in ensuring that the INR is measured consistently in different environments. Institutions such as the UK National External Quality Assessment Scheme for Blood Coagulation play a pivotal role in this process.

In contrast, no EQA scheme for warfarin dosing has been developed. Thus, although we may be confident that the measured INR is accurate, we cannot be sure whether the appropriate management decision has been taken by the responsible clinician. There has been little interest in assessing the quality of dosing decisions based on the derived INR. Therapeutic INR control has historically been poor; however, CDSS provides an opportunity for improvement. In parallel, it should be possible to undertake quality assessment procedures to ensure reliable performance.

We report the first data from a novel scheme designed to develop an EQA scheme for warfarin dosing for BAP-PC users. The primary function of BAP-PC is to convert patient derived INR into a warfarin dose.

METHOD

The software is installed on a practice computer running Windows 95 or later Windows upgrades. BAP-PC is installed independently from the clinical system. After each anticoagulation clinic, the software’s backup facility is used to transfer data on to a floppy disk. Once a year, each practice participating in the EQA uses the software feature “Export data to Birmingham” to save data on to floppy disks and send to the department of primary care and general practice at Birmingham University. By using this function, all data are anonymised with only a unique patient number for identification by practice received. All data were analysed for each individual practice, in addition to being pooled into an aggregate of user data. All practices that had used BAP-PC for the defined study period were eligible to participate.

Data used for the EQA process were as follows:

1. The number of patients on warfarin who have had at least one consultation within the audit period.

Abbreviations: BAP-PC, Birmingham Anticoagulation Programme for Primary Care; CDSS, computerised decision support software; EQA, external quality assessment; INR, international normalised ratio
RESULTS

Ten practices were able to provide complete data sets for the period 1 January 2001 to 1 January 2002. These data comprised a patient population of 367 on warfarin treatment (representing 250 patient years). The practice sizes varied from 17 to 65 patients.

Adverse events were classified as serious or non-serious, and defined as any bleeding or thrombotic episodes occurring while on warfarin. Serious events were defined as those requiring medical intervention. The total number of adverse events was 33 (0–13/practice). There were four serious adverse events (0–1/practice), which translates into a serious events rate of 1.6/100 patient years (table 1).

All adverse events were haemorrhagic episodes (table 2), with serious adverse events comprising one each of: cerebral infarct, intracranial bleeding (died of cerebral bleeding), gastrointestinal bleeding (patient died later of a combination of septicaemia, infective endocarditis, and cerebrovascular accident), and epistaxis (patient died one month later of carcinoma of the bronchus).

On average, patients spent 69% of time in range, 58% of patient visits were in range, and patients were being seen every 27 days. The average point prevalence was 86%. Time in range varied from 60% to 76% between practices, visits in range between 53% and 70%, and point prevalence values ranged from 76% to 100% (table 3).

DISCUSSION

Participating practices were representative of service general practices and came from a wide socioeconomic background. All practices had received training through the university department in oral anticoagulation management before establishing their service. The therapeutic management data are consistent with previously published data from primary care, both within and without clinical trials.21–22

However, there are doubts about the quality of data collection at practice level, because half of the practices reported no adverse events. Of course, this could mean that none had occurred, but it may be that they were not recorded. The rate of serious adverse events of 1.6/100 patient years is lower than some previously published data.16–17 Whereas Palareti et al stated a rate of major haemorrhagic events of 1.4,18 Cannegieter et al gave a rate of 2.3.22 Our results may represent a degree of under-recording.

Further research needs to be undertaken into how individual practices define and distinguish between serious and non-serious adverse events. Standardisation of definitions of adverse events would facilitate more accuracy in reporting thromboembolic and haemorrhagic episodes, and thus enhance the quality of external assessment.23 Further cycles of the EQA scheme will be required to establish whether this process is useful to practices and also as a research tool.

“We feel that our study has demonstrated proof of principle and that further developments are necessary to ensure a useful resource in the same way that we now have a national scheme for external quality assessment of international normalised ratio measurement.”

We are aiming to develop this scheme to include all practices using BAP-PC. We believe that the Birmingham EQA serves as an additional safeguard to ensure good practice in oral anticoagulation management. We would like to see similar data published from other software manufacturers, and would welcome the chance to combine data to provide a more comprehensive analysis. We feel that our study has demonstrated proof of principle and that further developments are necessary to ensure a useful resource in the same way that we now have a national scheme for EQA of INR measurement. This EQA may be useful as a benchmarking tool for practices in that their individual results are shown in comparison to the aggregate result of all practices using BAP-PC over the same time period. With the anticipated further devolution of anticoagulation services to primary care, the need for such benchmarking becomes more important. We will also need to deal

---

**Table 1** Adverse events

<table>
<thead>
<tr>
<th>Type of Adverse Event</th>
<th>Mean</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events</td>
<td>3.3</td>
<td>0–13</td>
</tr>
<tr>
<td>Non-serious adverse events</td>
<td>2.9</td>
<td>0–12</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>0.4</td>
<td>0–1</td>
</tr>
</tbody>
</table>

**Table 2** Haemorrhagic and thromboembolic adverse events

<table>
<thead>
<tr>
<th>Type of Adverse Event</th>
<th>Haemorrhagic adverse events</th>
<th>Thromboembolic adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse events</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Non-serious adverse events</td>
<td>29</td>
<td>0</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>4</td>
<td>0</td>
</tr>
</tbody>
</table>

**Table 3** International normalised ratio control

<table>
<thead>
<tr>
<th>Type of Control</th>
<th>Mean (%)</th>
<th>Range (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time in range</td>
<td>69</td>
<td>60–76</td>
</tr>
<tr>
<td>Point prevalence</td>
<td>86</td>
<td>76–100</td>
</tr>
<tr>
<td>Visits in range</td>
<td>58</td>
<td>53–70</td>
</tr>
<tr>
<td>Review frequency(days)</td>
<td>27</td>
<td>24–30</td>
</tr>
</tbody>
</table>
Take home messages

- On average, patients spent 69% of the time in the therapeutic range (range, 60–76%), 33 adverse events were reported (0–13/practice), and serious adverse events ranged from 0 to 1 for each practice (serious adverse event rate of 1.6/100 patient years)
- Thus, BAP-PC enabled practices to maintain good therapeutic international normalised ratio control
- There are some doubts about the quality of data collection at a practice level because there were no reported events in half of the participating centres, although the observed event rates do agree with previously reported data
- Further cycles of the scheme are necessary to establish it as a useful research and benchmarking tool

with the issue of how to provide quality assurance for dosing for those patients undertaking self management.

ACKNOWLEDGEMENTS

Thanks to Dr A Riaz who designed the BAP-PC software. DF is supported by an NHS Career Scientist Award. EM is supported by an MRC Health Services Research Fellowship.

REFERENCES

External quality assessment for warfarin dosing using computerised decision support software

T P Oppenkowski, E T Murray, H Sandhar and D A Fitzmaurice

doi: 10.1136/jcp.56.8.605

Updated information and services can be found at:
http://jcp.bmj.com/content/56/8/605

These include:

References

This article cites 15 articles, 6 of which you can access for free at:
http://jcp.bmj.com/content/56/8/605#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/